Drug-Eluting Vascular Stent System
Hear in-depth commentary on IMPERIAL, the first head-to-head DES SFA Trial, including key insights and perspectives on how the data will impact treatment of PAD patients.
Hear William Gray, MD review the IMPERIAL Trial results.
Hear what physicians have to say about the challenges of treating the SFA and how drug-eluting vascuar stents may help improve patient outcomes.
Physicians talk about the importance of drug-eluting stents in complex lesions and how the Eluvia Drug-Eluting Stent is designed to deliver controlled, localized, low-dose amorphous paclitaxel to target lesions.
See how over a decade of research helped Eluvia engineers develop the first drug-eluting stent for the SFA designed to sustain drug release when restenosis is most likely.
Physicians discuss the tuned paclitaxel elution profile of the Eluvia Drug-Eluting Stent and how the stent has demonstrated unprecedented efficacy data in patients with peripheral artery disease (PAD).
See what physicians are saying about the unprecedented clinical outcomes for the Eluvia Drug-Eluting Stent, including two-year primary patency and TLR rates.
The Eluvia Drug-Eluting Stent System showed SUPERIOR results in the first head-to-head DES SFA Trial.
IMPERIAL Trial: A global randomized controlled multi-center trial with 2:1 randomization of the Eluvia™ Drug-Eluting Stent against Cook Medical’s Zilver™ PTX™ Stent, single-blind, non-inferiority design; independent core lab adjudication.
Superiority determined in a post hoc analysis that was specified prior to unblinding. 12-Month Primary Patency rate of 86.8% in the Eluvia arm vs. 77.5% in the Zilver PTX arm (p-value = 0.0144).
24-Month Primary Patency Results
* Intention to treat. Kaplan-Meier estimate with standard errors. Primary patency defined as duplex ultrasound PSVR ≤2.4, in the absence of clinically-driven target lesion revascularization or bypass of the target lesion, as assessed by the DUS core lab.
24-Month Safety Results*
- 85.8% of Eluvia patients were free from Major Adverse Events at 24 months (vs. 79.9% of Zilver PTX patients)
- All-cause mortality for Eluvia was 7.1% (21/295) vs. 8.3% (12/145) for Zilver PTX (p=0.6649)
Eluvia™ Drug-Eluting Vascular Stent System UPN and GTIN Codes
|Eluvia 6 mm x 40 mm x 130 cm||H74939294600410||08714729876571|
|Eluvia 6 mm x 60 mm x 130 cm||H74939294600610||08714729876588|
|Eluvia 6 mm x 80 mm x 130 cm||H74939294600810||08714729876595|
|Eluvia 6 mm x 100 mm x 130 cm||H74939294601010||08714729876601|
|Eluvia 6 mm x 120 mm x 130 cm||H74939294601210||08714729876618|
|Eluvia 7 mm x 40 mm x 130 cm||H74939294700410||08714729876694|
|Eluvia 7 mm x 60 mm x 130 cm||H74939294700610||08714729876700|
|Eluvia 7 mm x 80 mm x 130 cm||H74939294700810||08714729876717|
|Eluvia 7 mm x 100 mm x 130 cm||H74939294701010||08714729876724|
|Eluvia 7 mm x 120 mm x 130 cm||H74939294701210||08714729876731|